The mechanism of endocrine resistance in ER+ breast cancer includes the loss of ERα expression, the mutation of the ESR1 gene, and the activation of alternative signaling pathways, such as HER2 [41]. This evidence concerns the gene ERBB2 and breast carcinoma.